Neil E Martin1, Ming-Hui Chen2, Danjie Zhang2, Jerome P Richie3, Anthony V D'Amico4. 1. Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA. Electronic address: nmartin@lroc.harvard.edu. 2. Department of Statistics, University of Connecticut, Storrs, CT. 3. Department of Urology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA. 4. Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Some men with unfavorable intermediate-risk prostate cancer (PC) have occult disease with a Gleason score of 8 or higher unrecognized on biopsy because of a sampling error that would change management to long from short course androgen-deprivation therapy in conjunction with radiotherapy. Identifying such men could improve outcomes. PATIENTS AND METHODS: The study cohort consisted of 136 consecutive men with unfavorable intermediate-risk PC who underwent radical prostatectomy (RP) between 2005 and 2008. We performed logistic regression analysis to identify clinical factors associated with upgrading to a Gleason score of 8 or higher at RP. RESULTS: Fourteen percent of the men were upgraded to a Gleason score of 8 or higher PC at RP. Both increasing prostate-specific antigen (PSA) (adjusted odds ratio, 1.98; 95% confidence interval, 1.19, 3.30; P = .01) and greatest percentage core length (GPC) (adjusted odds ratio, 1.11; 95% confidence interval, 1.03, 1.19; P < .01) were significantly associated with upgrading. A significant interaction between PSA and GPC was observed (P = .01). Specifically, men with low PSA (< 5 ng/mL) and those with larger GPC (> 70%) were significantly more likely to have a Gleason score of 8 or higher at RP compared to men with low PSA and GPC of 70% or less (35% vs. 0%; P = .01), whereas the same was not true among men with PSA levels ≥ 5 ng/mL (16% vs. 9%; P = .36). CONCLUSION: In men with unfavorable intermediate-risk PC, a multiparametric magnetic resonance imaging could be considered when the PSA is low and the percentage core length high to identify occult Gleason score 8 or higher disease and change management from short to long course androgen-deprivation therapy and radiotherapy.
BACKGROUND: Some men with unfavorable intermediate-risk prostate cancer (PC) have occult disease with a Gleason score of 8 or higher unrecognized on biopsy because of a sampling error that would change management to long from short course androgen-deprivation therapy in conjunction with radiotherapy. Identifying such men could improve outcomes. PATIENTS AND METHODS: The study cohort consisted of 136 consecutive men with unfavorable intermediate-risk PC who underwent radical prostatectomy (RP) between 2005 and 2008. We performed logistic regression analysis to identify clinical factors associated with upgrading to a Gleason score of 8 or higher at RP. RESULTS: Fourteen percent of the men were upgraded to a Gleason score of 8 or higher PC at RP. Both increasing prostate-specific antigen (PSA) (adjusted odds ratio, 1.98; 95% confidence interval, 1.19, 3.30; P = .01) and greatest percentage core length (GPC) (adjusted odds ratio, 1.11; 95% confidence interval, 1.03, 1.19; P < .01) were significantly associated with upgrading. A significant interaction between PSA and GPC was observed (P = .01). Specifically, men with low PSA (< 5 ng/mL) and those with larger GPC (> 70%) were significantly more likely to have a Gleason score of 8 or higher at RP compared to men with low PSA and GPC of 70% or less (35% vs. 0%; P = .01), whereas the same was not true among men with PSA levels ≥ 5 ng/mL (16% vs. 9%; P = .36). CONCLUSION: In men with unfavorable intermediate-risk PC, a multiparametric magnetic resonance imaging could be considered when the PSA is low and the percentage core length high to identify occult Gleason score 8 or higher disease and change management from short to long course androgen-deprivation therapy and radiotherapy.
Authors: Gabriele Sorce; Rocco Simone Flammia; Benedikt Hoeh; Francesco Chierigo; Lukas Hohenhorst; Andrea Panunzio; Armando Stabile; Giorgio Gandaglia; Zhe Tian; Derya Tilki; Carlo Terrone; Michele Gallucci; Felix K H Chun; Alessandro Antonelli; Fred Saad; Shahrokh F Shariat; Francesco Montorsi; Alberto Briganti; Pierre I Karakiewicz Journal: Prostate Date: 2022-04-01 Impact factor: 4.012